title: [Development of a second generation prophylactic vaccine against human papillomavirus].
abstract: Human papillomaviruses (HPV) are the etiologic agent for cervical cancer (CC), the second cause of cancer death in women worldwide. It is estimated that half a million new cases are diagnosed each year, mostly in developing countries due to the lack of massive programs for early detection of the virus. Recently, two prophylactic vaccines against the main oncogenic HPV types 16 and 18 (responsible for 80% of CC) have been introduced into market. Both of these vaccines, obtained as recombinants, have been shown to be safe and effective; however, their high cost works against its immediate impact in the incidence of HPV infection in developing and low-income countries. There is a need to have in hand second generation, low cost vaccines of massive use that will decrease CC cases in a large extent. With this in mind, we have developed a recombinant expression platform that allows us to obtain virus-like particles (VLPs) to formulate both effective and accessible vaccines against HPV infection.
authors: XBio S.A.
authors: Alonso
authors: A
authors: Leonardo
authors: María Laura
authors: ML
authors: Cerutti
authors: Marikena
authors: M
authors: Risso
authors: Mariángeles
authors: M
authors: González
authors: Gabriela
authors: G
authors: Camporeale
authors: Gonzalo
authors: G
authors: de Prat Gay
mesh_terms: D000818:Animals; D003906:Developing Countries; D005260:Female; D006801:Humans; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000191:economics; D011817:Rabbits
chemical_list: D053918:Papillomavirus Vaccines; C510352:human papillomavirus vaccine, L1 type 16, 18